Extramedullary plasmacytoma of the larynx manifesting as chronic hypertrophic laryngitis

Szczepanek, Elżbieta; Rzepakowska, Anna; Końska, Agnieszka; Niemczyk, Kazimierz; Hus, Iwona; Grzybowski, Jakub; Jamroziak, Krzysztof

doi:10.5603/ahp.a2022.0027

Cited by 1 publication

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient was qualified for radical 3D-MRT (three-dimensional magnetic resonance tomosynthesis) radiotherapy to the larynx, which resulted in complete remission. At the last follow-up visit, 18 months post-treatment, no local recurrence or progression to the systemic form of PCM was found [ 8 ]. The second patient, a 59-year-old man, was referred to the Department of Otorhinolaryngology due to the polypoid mass localised on the epiglottis and right aryepiglottic fold (no symptoms were observed—accidental finding).…”

Section: Resultsmentioning

confidence: 99%

“…Factors predisposing to laryngeal involvement by PCM have not been identified. It is, however, worth noting, that in two out of six patients from our retrospective analysis, repeated larynx biopsies revealed chronic inflammation in histopathological examination and only a subsequent biopsy material allowed for a diagnosis of extramedullary disease [ 8 ]. It cannot be excluded that chronic inflammation did trigger mutagenesis and, in consequence, the development of PCM at the site of inflammation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Solitary Extramedullary Plasmacytoma of the Larynx and Secondary Laryngeal Involvement in Plasma Cell Myeloma: Single-Centre Retrospective Analysis and Systematic Literature Review

Szczepanek

Drozd-Sokołowska

Sokołowski

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

The involvement of the larynx in plasma cell myeloma (PCM) may manifest as solitary extramedullary plasmacytoma of the larynx (sEMP-L) or as infiltration of the larynx during newly diagnosed or relapsed systemic disease with bone marrow involvement (plasma cell myeloma with laryngeal involvement, PCM-L). To increase knowledge about these rare conditions, we performed a retrospective analysis along with a comprehensive literature review of cases of sEMP-L or PCM-L. Six patients (two sEMP-L and four PCM-L) were identified in our tertiary laryngological centre from 2009 to 2021, constituting 0.88% of all malignant laryngeal tumours. The literature search yielded 187 cases, including 152 sEMP-L and 35 sPCM-L. A comparison of baseline characteristics between sEMP-L and PCM-L performed in the combined cohort of cases from literature review and retrospective analysis revealed that patients with sEMP-L were younger (56 vs. 64 years, p ≤ 0.001) and presented less commonly with thyroid or cricoid cartilage involvement (2.2% vs. 30.8%, p ≤ 0.001). The prognosis of sEMP-L was better than PCM-L (overall survival 86% vs. 55% at 5 years, p = 0.002). Analysis of potential factors that could influence progression-free survival (PFS) in the group of sEMP-L revealed that male sex and cartilage involvement negatively affected PFS in univariate analyses, while only cartilage involvement retained statistical significance in multivariate analysis (HR = 19.94, p = 0.024). In conclusion, PCM with laryngeal involvement is sporadic. Secondary involvement of the larynx during PCM might be more common than sEMP-L and is associated with worse survival. The involvement of cartilage adversely influences the outcome of sEMP-L.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%